Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort Study.
AuteursDauccia C, Martins-Branco D, Moreau M, Ameye L, Agostinetto E, Arecco L, Lobo-Martins S, Skoporc A, Vilas-Boas I, Auprih M, Awada A, Debien V, de Azambuja E
Tumor-stroma proportion on primary tumor as a prognostic biomarker in advanced ovarian cancer patients receiving chemo-immunotherapy as first-line therapy: analyses from the NeoPembrOV/GINECO phase II randomized trial.
AuteursCollet L, Noël JC, Catteau X, Ardin M, Berthet J, Ghamry-Barrin S, Treilleux I, Bengrine Lefevre L, Martinez M, Rothé F, Sotiriou C, Caux C, Dubois B, Ray-Coquard I, Le Saux O
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.
AuteursGarcía-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J
Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer.
AuteursBardia A, Rugo HS, Sedrak MS, Loibl S, Tolaney SM, Punie K, Hurvitz SA, Kalinsky KM, Cortés J, O'Shaughnessy JA, Dieras V, Piccart-Gebhart MJ, Dasgupta A, Kaushik A, Lai C, Shi L, Brufsky A
Adverse events and impact on quality of life of antibody-drug conjugates in the treatment of metastatic breast cancer: A systematic review and meta-analysis.
AuteursPerachino M, Blondeaux E, Molinelli C, Ruelle T, Giannubilo I, Arecco L, Nardin S, Razeti MG, Borea R, Favero D, Lanzavecchia C, Chiappe E, Tomasello L, Mariamidze E, Jankovic K, Stana M, Ottonello S, Scavone G, de Moura Leite L, Spinaci S, Saura C, Lambertini M
